New compounds for the treatment of neurological, psychiatric or pain disorders

Abstract

The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.

1 . A compound of formula III  
       
         
           
           
               
               
           
         
       
       as well as a pharmaceutically acceptable salt, hydrate and/or isoform thereof.  
     
     
         2 . The compound according to  claim 1  in crystalline form.  
     
     
         3 . A pharmaceutical composition comprising a compound according to  claim 1  or  2  as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.  
     
     
         4 . A method for the treatment or prevention of a mGluR5 receptor-mediated disorder, wherein an effective amount of a compound according to  claim 1  or  2  is administered to a subject in need of such treatment or prevention.  
     
     
         5 . The method according to  claim 4 , wherein said disorder is a neurological disorder.  
     
     
         6 . The method according to  claim 4 , wherein said disorder is a psychiatric disorder.  
     
     
         7 . The method according to  claim 4 , wherein said disorder is any one of gastroesophageal reflux disease, IBS, functional dyspepsia, cough, obesity, Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders such as retinopathies, diabetic retinopathies, glaucoma, auditory neuropathic disorders such as tinnitus, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders such as diabetic neuropathies, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with various conditions including angina, renal or billiary colic, menstruation, migraine and gout; stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.  
     
     
         8 . The method according to  claim 7 , wherein said disorder is a chronic pain disorder.  
     
     
         9 . The method according to  claim 7 , wherein said disorder is an acute pain disorder.  
     
     
         10 . The method according to  claim 7 , wherein said disorder is anxiety.  
     
     
         11 . The method according to  claim 7 , wherein said disorder is depression.  
     
     
         12 . The method according to  claim 7 , wherein said disorder is Parkinson's disease.  
     
     
         13 . The method according to  claim 7 , wherein said pain disorder is a neuropathic pain disorder.  
     
     
         14 . The method according to  claim 7 , wherein said pain disorder is migraine.  
     
     
         15 . The method according to  claim 7 , wherein said pain disorder is inflammatory pain.  
     
     
         16 . The method according to  claim 7 , wherein said disorder is gastroesophageal reflux disease.  
     
     
         17 . The method according to  claim 7 , wherein said disorder is cough.